Preparation, physicochemical characterization, dissolution and formulation studies of telmisartan cyclodextrin inclusion complexes

Main Article Content

Rajesh N Kane
Bhanudas S Kuchekar


The objective of this research was to prepare, characterize, and to study dissolution properties of inclusion complexes of telmisartan (TLM), with β-cyclodextrin and hydroxypropyl-β-cyclodextrin and to study effect of complexation on aqueous solubility and rate of dissolution in dissolution media. The phase solubility curve was classified as an AP type for
both the CDs, which indicated formation of the inclusion complex of TLM in 1:2 stoichiometries with β-CD and HP-β-CD. The inclusion complexes in molar ratio of 1:2 were prepared by various methods. The molecular behavior of TLM in all
samples were characterized by Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), and powder X-ray diffraction studies.The result of studies showed inclusion of TLM molecule into cyclodextrin cavities.The
highest improvement in in-vitro dissolution of TLM was observed in a complex prepared with HPβ-CD using the kneading method. Mean dissolution time (MDT) and similarity factor (f2) indicated a significant difference between the release profile of TLM from complexes, physical mixture, and pure TLM. The highest improvement in solubility and in-vitro drug release were observed in inclusion complex prepared with HP-β-CD by kneading method. Improvement in solubility and in-vitro drug release of telmisartan was more with HP-β-CD as compared to β-CD


Download data is not yet available.

Article Details

How to Cite
Kane, R. N., & Kuchekar, B. S. (2014). Preparation, physicochemical characterization, dissolution and formulation studies of telmisartan cyclodextrin inclusion complexes. Asian Journal of Pharmaceutics (AJP), 4(1).


Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan:

A selective AT1 receptor antagonist, compared with enalapril in elderly

patients with primary hypertension: TEES Study Group. J Hypertens


Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneben H, Entzeroth M,

et al. 6-Substituted benzimidazoles as new nonpeptide angiotensin

II receptor - antagonists: Synthesis, biological activity, and structure-

activity relationships. J Med Chem 1993;36:4040-51.

Mallion JM, Siche JP, Lacourcière Y. ABPM comparison of the

antihypertensive profiles of the selective angiotensin II receptor

antagonists telmisartan and losartan in patients with mild to moderate

hypertension. J Hum Hypertens 1999;13:657-64.

Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec

M, et al. Identification of telmisartan as a unique angiotensin II

receptor antagonist with selective PPARgamma-modulating activity.

Hypertension 2004;43:993-1002.

P ro d u c t I n f o r m a t i o n : M i c a rd i s ® H C T, t e l m i s a r t a n a n d

hydrochlorothiazide. Boehringer Ingelheim, Ridgefield, Connecticut.

(PI revised 11/2000) reviewed 1/2001.

Proudfoot S. Factors affecting bioavailability: Factors influencing

drug absorption from the gastrointestinal tract. In: Aulton ME, editor.

Pharmaceutics, the science of dosage form design. UK: Churchill

Livingstone London; 1991. p. 135-73.

Cappello B, Clelia DM, Iervolino M, A. Improvement of solubility and

stability of valsartan by hydroxypropyl-boldbeta-cyclodextrin. J Incl

Phenom Macro Chem 2006;54:289-94.

Patel R, Patel M. Solid-state characterization and dissolution properties

of lovastatin hydroxypropyl-β-cyclodextrin inclusion complex. Pharm

Tech 2007; February 2:72-81.

Becket G, Schep LJ, Tan MY. Improvement of the in vitro dissolution

of praziquantel by complexation with alpha, beta and gamma

cyclodextrin. Int J Pharm 1999;179:65-71.

Higuchi T, Connors K. Phase solubility techniques. Adv Anal Chem

Instru 1965;4:17-123.

Moore JW, Flanner H. Mathematical comparison of dissolution profiles.

Pharm Tech 1996;20:64-74.

US food and drug administration, guidance for industry SUPAC-MR:

Modified release solid oral dosage forms scale-up and postapproval

changes: Chemistry, manufacturing, and controls; In vitro dissolution

testing and in vivo bioequivalence documentation. Rockville, MD:

FDA; 1997.

Human medicines evaluation unit, European agency for the Evaluation

of Medicinal Products (EMEA), Notes for guidance on quality of

modified-release products: A oral dosage forms; B transdermal dosage

forms, Section 1 (Quality). London, UK: EMEA; 1999.

Reppas C, Nicolaides E. Analysis of drug dissolution data. In: Dressman JB, Lennerna’s H, editors. Oral drug absorption prediction and

assessment. New York: Marcel Decker; 2000. p. 229-54.

Vueba ML, Batista de Carvalho LA, Veiga F, Sousa JJ, Pina ME. Influence

of cellulose ether polymers on ketoprofen release from hydrophilic

matrix tablets. Eur J Pharm Biopharm 2004;58:1-59.

Costa FO, Sousa JJ, Formosinho SJ. Comparison of dissolution profiles

of Ibuprofen pellets. J Control Release 2003;89:199-212.

Rinaki E, Dokoumetzidis A, Macheras P. The mean dissolution time

depends on the dose/solubility ratio. Pharm Res 2003;20:406-8.

Loftsson T, Magnusdottir AM, Masson JF, Sigurjonsdottir. Self-association

and cyclodextrin solubilization of drugs. J Pharm Sci 2002;91:2307-16.

Most read articles by the same author(s)